Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines
Results published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent and selective drug candidates
The first PROTAC is made freely available via Boehringer Ingelheim’s open innovation portal, opnMe
Structure-based PROTAC design promises to accelerate the development of therapies against currently intractable cancer drivers
INGELHEIM, Germany & DUNDEE, Scotland -- (BUSINESS WIRE) --
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins. This brings together the expertise of Professor Alessio Ciulli, one of the pioneers in the field of Proteolysis targeting chimeras (PROTACs), based in the School of Life Sciences at Dundee, with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bring innovative medicines to patients with cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005444/en/
PROTACs represent a new class of drug candidates with the potential to tackle compelling cancer targets which have failed traditional medicinal chemistry approaches. They work by harnessing the cell’s natural disposal system (the ubiquitin-proteasome). Candidate disease-causing proteins are labelled as “expired” proteins which the proteasome then shreds.
“PROTACs are a disruptive therapeutic modality which are bringing previously deemed undruggable targets within reach. Our collaboration will continue to work to bring this new class of medicines to patients,” said Darryl B. McConnell, Ph.D., Senior Vice President and Research Site Head, Boehringer Ingelheim, Vienna, Austria. “The joint team is making rapid progress and have successfully reached the first collaboration milestone setting a solid basis for achieving our goals.”
Since the initiation of the collaboration in 2016 and a significant expansion in 2018, the application of PROTACs has grown dramatically. However, designing PROTACs remains challenging and largely empirical in nature, hindering faster progress in the field. The partners have thus developed a structure-based design approach as a solid basis to accelerate further development. In addition, to boost PROTAC research around the world, Boehringer Ingelheim has made the protein degrader compound MZ-1, developed at the University of Dundee, freely available through its opnMe portal in 2018. Further PROTAC molecules are considered for release on opnMe based on the success of this initiative.
The joint team has reported recent progress in a number of scientific publications, including most recently in the journal Nature Chemical Biology. This publication highlights their approach to use 3-dimensional pictures at atomic resolution to design highly potent and selective drug candidates. The new approach has yielded the first PROTAC which shreds SMARCA2, a protein that drives the tumors of more than 20,000 new patients with cancer each year and for which drug discovery approaches have otherwise been unsuccessful to date.
“Our joint publication is a leading example of translating the detailed understanding we are developing of how PROTACs work, to craft degrader molecules that effectively tackle previously ‘undruggable’ targets”, said Alessio Ciulli, Ph.D., Chair of Chemical and Structural Biology at the University of Dundee, and winner of the 2016 RSC Capps Green Zomaya Award for medicinal chemistry. “The expansion marks an important milestone in the development of our alliance. It enables the joint team to drive the next phase of degrading highly-prized cancer targets previously intractable via other approaches”
Boehringer Ingelheim is focusing on developing innovative new treatment approaches providing outstanding value for patients. To achieve this, the company is increasing its commitment to external innovation, and is working with top partners from academia and industry worldwide. A growing network of academic collaborations reflects the company’s focus on emerging science that could open new avenues leading to the breakthrough medications of the future.
Please click on the link for “Notes to Editors” and “References”:
Boehringer Ingelheim Launches
Carestream Health将其医疗保健IT业务
DCAS开始接受2024年非经销商委员会会员申请
Vifor Pharma and Angion
Rimini Street荣获多项客户销售与服务世界奖
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
Spesolimab meets primary
Aeternals:新型NFT和互动技术相结合
面对疫情和经济危机,亿康先达发布强劲的20
苏爱康医药宣布在日本推出Darvias®
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Mythical Games完成3700万美元C1轮融资
IDEMIA和Resa Airport Data Syst
电池生产商Hithium将为储能系统开发商Perfect
Sabre选择DXC Technology来助力改变未
Kymeta 宣布其下一代天线、终端和全球移动连接
深圳三匹马出行科技与江铃集团新能源战略合作
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商
Mavenir的虚拟无线接入网(vRAN)连续第二年在
广成明股份参加番禺区先进制造业强区座谈会
森永乳业的益生菌长双歧杆菌BB536在其50周年庆
在大地上书写责任与担当——渭南师范学院孙樵
Intelsat向史密森国家航空航天博物馆捐赠
全球投资者法律顾问ROSEN鼓励Athira Pharma